Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children

Simple item page
dc.contributor.authorKekitiinwa, Adeodata.
dc.contributor.authorMusiime, Victor.
dc.contributor.authorThomason, Margaret J.
dc.contributor.authorMirembe, Grace
dc.contributor.authorLallemant, Marc
dc.contributor.authorNakalanzi, Sarah.
dc.contributor.authorBaptiste, David.
dc.contributor.authorWalker, Sarah A.
dc.contributor.authorGibb, Diana M.
dc.contributor.authorJudd, Ali
dc.date.accessioned2021-12-10T11:12:05Z
dc.date.available2021-12-10T11:12:05Z
dc.date.issued2016
dc.description.abstractLopinavir/ritonavir ‘pellets’ were recently tentatively approved for licensing. We describe their acceptability for infants and children up to 48 weeks. Methods—CHAPAS-2 was a randomised, 2-period crossover trial comparing syrup and pellets in HIV-infected infants (n=19, group A, aged 3-<12 months) and children (n=26, group B, 1-<4yrs) and tablets and pellets in older children (n=32, group C, 4-<13yrs) from 2 clinics (“JCRC”, “PIDC”) in Uganda. At week 8, all groups chose which formulation to continue. Acceptability data were collected at weeks 0,4,8,12, and 48. Results—For groups A and B overall, the proportion preferring pellets increased between week 0 and week 12 and decreased at week 48 (group A 37%, 72%, 44%; group B 12%, 64% and 36% respectively), although there were marked differences between clinics. For group C, pellets were progressively less preferred to tablets over time: 41%,19%,13% at weeks 0,12,48 respectively. During follow-up unpleasant taste was similarly reported among young children taking pellets and syrups (37%/43% group A; 29%/26% group B), whereas among older children, pellets tasted worse than tablets (40%/2%). No participants reported problems with storage/transportation for pellets (0%/0%) unlike syrups (23%/13%). Conclusions—For children <4 years, pellets were more acceptable at week 12 but not week 48. Clinic differences could reflect bias among healthcare workers for different formulations. Pellets taste similar to syrup, are easier to store and transport than syrup, and represent an alternative formulation for young children unable to swallow tablets; improvements in taste and support for healthcare workers may help sustain acceptabilityen_US
dc.identifier.citationKekitiinwa, A., Musiime, V., Thomason, M. J., Mirembe, G., Lallemant, M., Nakalanzi, S., ... & Judd, A. (2016). Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antiviral therapy, 21(7), 579.doi:10.3851/IMP3054.en_US
dc.identifier.other10.3851/IMP3054.
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/244
dc.language.isoenen_US
dc.publisherEurope PMC Funders Groupen_US
dc.subjectLopinaviren_US
dc.subjectritonaviren_US
dc.subjectpelletsen_US
dc.subjectminitabsen_US
dc.subjectacceptabilityen_US
dc.subjectchildrenen_US
dc.titleAcceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected childrenen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Acceptability of lopinavirr pellets (minitabs), tablets and syrups in HIV-infected children.pdf
Size:
574.33 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences